Characterization of patients with portal vein thrombosis on non-cirrhotic liver at a university hospital in Medellín, Colombia
DOI:
https://doi.org/10.59093/27112330.123Keywords:
thrombosis, portal vein, anticoagulation, thrombophilia, portal hypertension.Abstract
Introduction. Portal vein thrombosis is the partial or complete occlusion of the lumen of the portal vein or its tributaries by thrombus formation. It is associated with adverse outcomes and a poorer prognosis. Its frequency is increasing, often incidentally, due to the growing use of diagnostic imaging. Methodology. This is an observational study of a case series of patients over 18 years old who were documented with portal vein thrombosis in a non-cirrhotic liver between January 2012 and December 2019 in a fourth-level hospital in the city of Medellín, Colombia. Results. Ninety-four cases of portal vein thrombosis were documented. The mean age was 44 ± 15 years, and 56 % were women. The average onset of symptoms was 14 days. Thrombosis presentation was acute in 41 %, chronic in 44 %, and acute on chronic in 15 %. Clinically, 33 % were asymptomatic, and abdominal pain was the most common presentation at 62 %. The most common acquired thrombophilia was chronic myeloproliferative neoplasms at 18 %, followed by antiphospholipid syndrome at 6 %. The most used diagnostic method was triphasic CT at 58 %, followed by ultrasonography at 35 %. Sixty-six percent of the patients received anticoagulation, with warfarin being the main anticoagulant used at 56 %. Sixteen percent experienced some type of bleeding, although none were major. Conclusions. Portal vein thrombosis remains, in many cases, an incidental finding. An unusual number of chronic myeloproliferative neoplasms were found. Anticoagulation is safe and effective, although the
use of direct oral anticoagulants remains restricted.
Downloads
References
Sarin SK, Sollano JD, Chawla YK, Amarapurkar D, Hamid S, Hashizume M, et al. Consensus on extra-hepatic portal vein obstruction. Liver Int 2006 Jun;26:512-519. https://doi.org/10.1111/j.1478-3231.2006.01269.x.
Loudin M, Ahn J. Portal vein thrombosis in cirrhosis. J Clin Gastroenterol 2017;51:579-585. https://doi.org/10.1097/MCG.0000000000000857.
Basit SA, Stone CD. Portal vein thrombosis. Clin Liver Dis 2015;19:199-221. https://doi.org/10.1016/j.cld.2014.09.012.
Qi X, Ren W, De Stefano V, Fan D. Associations of coagulation factor V Leiden and prothrombin G20210A mutations with Budd-Chiari syndrome and portal vein thrombosis: A systematic review and meta-analysis. Clin Gastroenterol Hepatol 2014;12:1801-1812.e7. https://doi.org/10.1016/j.cgh.2014.04.026.
Sarin SK, Kamath PS, Choudhury A, Maruyama H, Nery FG, Valla DC, et al. Toward a comprehensive new classification of portal vein thrombosis in patients with cirrhosis. Gastroenterology 2016 Oct;151:574-577.e3. https://doi.org/10.1053/j.gastro.2016.06.012.
Kumar A, Sharma P, Arora A. Review article: portal vein obstruction – Epidemiology, pathogenesis, natural history, prognosis and treatment. Aliment Pharmacol Ther 2015 Feb;41:276-292. https://doi.org/10.1111/apt.13019.
Intagliata NM, Caldwell SH, Tripodi A. Diagnosis, development, and treatment of portal vein thrombosis in patients with and without cirrhosis. Gastroenterology 2019 Jun;156:1582-1599.e1. https://doi.org/10.1053/j.gastro.2019.01.265.
Ögren M, Bergqvist D, Björck M, Acosta S, Eriksson H, Sternby NH. Portal vein thrombosis: Prevalence, patient characteristics and lifetime risk: A population study based on 23,796 consecutive autopsies. World J Gastroenterol 2006;12:2115-2119. https://doi.org/10.3748/wjg.v12.i13.2115.
Qi X, Wu F, He C, Fan D, Han G. Thrombotic risk factors in Chinese nonmalignant and noncirrhotic patients with portal vein thrombosis: an observational study with a systematic review of the literature. Eur J Gastroenterol Hepatol 2015;27:77-83. https://doi.org/10.1097/MEG.0000000000000221.
Margini C, Berzigotti A. Portal vein thrombosis: The role of imaging in the clinical setting. Dig Liver Dis 2017;49:113-120. https://doi.org/10.1016/j.dld.2016.11.013.
Hidajat N, Stobbe H, Griesshaber V, Schröder RJ, Vogl TJ, Felix R. Imaging and radiological interventions of portal vein thrombosis. Acta Radiol 2005;46:336-343. https://doi.org/10.1080/02841850510021157.
Choy G, Zhu A, Hahn PF. Differentiation of malignant thrombus from bland thrombus of the portal vein in patients with hepatocellular carcinoma: Application of diffusion-weighted MR imaging. Radiology 2010;254:154-162. https://doi.org/10.1148/radiol.09090304.
Primignani M. Portal vein thrombosis, revisited. Dig Liver Dis 2010;42:163-170. https://doi.org/10.1016/j.dld.2009.08.003.
Battista G, Sandri L, Lai Q, Berloco PB, Rossi M. Portal vein thrombosis before liver transplant does not alter postoperative patient or graft survival. Exp Clin Transplant 2014;12:238-240. https://doi.org/10.6002/ect.2013.0257.
Plessier A, Darwish-Murad S, Hernandez-Guerra M, Consigny Y, Fabris F, Trebicka J, et al. Acute portal vein thrombosis unrelated to cirrhosis: A prospective multicenter follow-up study. Hepatology. 2010 Jan;51(1):210-218. doi: 10.1002/hep.23259.
Turnes J, García-Pagán JC, González M, Aracil C, Calleja JL, Ripoll C, et al. Portal hypertension-related complications after acute portal vein thrombosis: Impact of early anticoagulation. Clin Gastroenterol Hepatol 2008 Dec;6:1412-1417. https://doi.org/10.1016/j.cgh.2008.07.031.
Weinberg EM, Palecki J, Reddy KR. Direct-acting oral anticoagulants (DOACs) in cirrhosis and cirrhosis-associated portal vein thrombosis. Semin Liver Dis 2019;39:195-208. https://doi.org/10.1055/s-0039-1679934.
European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines: Vascular diseases of the liver. J Hepatol 2016;64:179-202. https://doi.org/10.1016/j.jhep.2015.07.040.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 The authors retain all copyright and grant the Colombian Association of Hepatology a non-exclusive right to publish and disseminate their work.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Hepatología’s authorship policy is based on the criteria established by the International Committee of Medical Journal Editors (ICMJE) to credit a person for their work while assigning them responsibility for its publication.
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |















